HOME >> BIOLOGY >> NEWS
Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer

Rochester, Minn. -- Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.

In effect, the Mayo Clinic virus makeover uses proteins secreted by cancer cells as the unique key to the virus' ignition. Their report on the topic appears in the Aug. 1 edition of Cancer Research (http://cancerres.aacrjournals.org).

The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."

Significance of the Mayo Clinic Research
The Mayo researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.

As such, the Mayo innovation of the cancer-activated virus is a helpful safety advance for the promising experimental field of "oncolytic virotherapy." The phrase refers to t
'"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
1-Aug-2006


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis
5. Clinical trial for diabetic macular edema
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
8. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
9. Marshfield Clinics electronic health record first to receive CCHIT certification
10. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
11. October MCP: A special issue on Clinical Proteomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/12/2019)... ... November 12, 2019 , ... In’Tech Medical SAS ( ... the creation of a Global Regulatory Affairs Department, to support Medical Device companies ... the regulatory element to any Medtech organization is more important than Research & ...
(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, the world leader in ... in the award-winning study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee ... processed samples using Next Generation DNA Sequencing to examine the ability of NGS ...
(Date:11/6/2019)... ... November 06, 2019 , ... In October, Massachusetts stem cell ... patients about a poorly disclosed deficiency in stem cell treatments. Throughout stem ... the treating stem cells. This problem affects all patients receiving stem cell ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma ... students at South Dakota School of Mines & Technology are exploring new ... healthy cells alive. , If successful, the technique would prove to be a ...
(Date:10/29/2019)... Conn. (PRWEB) , ... October 28, 2019 , ... ... Advisory Board: , , Professor Jack R Wands, MD, of ... and Wyeth (Pfizer) , Professor Gil Mor, MD, PhD, of Wayne State ...
(Date:10/29/2019)... , ... October 29, 2019 , ... ... of the skin*. Using Silios CMS-C multispectral imagers , researchers identified people ... can replace identification based on retinal imaging, face recognition, fingerprints and vasculature. ...
(Date:10/22/2019)... (PRWEB) , ... October 22, 2019 , ... nQ Medical, ... Business School’s 2019 Most Fundable Companies List which was announced at a showcase event ... $10 million in annual revenue, strong business plans, and impressive near-term growth projections to ...
Breaking Biology Technology:
Cached News: